Iris de Weerdt

861 total citations
16 papers, 644 citations indexed

About

Iris de Weerdt is a scholar working on Genetics, Immunology and Oncology. According to data from OpenAlex, Iris de Weerdt has authored 16 papers receiving a total of 644 indexed citations (citations by other indexed papers that have themselves been cited), including 13 papers in Genetics, 11 papers in Immunology and 8 papers in Oncology. Recurrent topics in Iris de Weerdt's work include Chronic Lymphocytic Leukemia Research (13 papers), Immune Cell Function and Interaction (9 papers) and CAR-T cell therapy research (8 papers). Iris de Weerdt is often cited by papers focused on Chronic Lymphocytic Leukemia Research (13 papers), Immune Cell Function and Interaction (9 papers) and CAR-T cell therapy research (8 papers). Iris de Weerdt collaborates with scholars based in Netherlands, United States and Canada. Iris de Weerdt's co-authors include Arnon P. Kater, Michel van Gelder, Jeffrey L. Jorgensen, Mark‐David Levin, Jan A. Burger, Julia Hoellenriegel, Elena Hartmann, Gracy Zacharian, Alessandra Ferrajoli and Naveen Garg and has published in prestigious journals such as Blood, The Journal of Immunology and Cancer Research.

In The Last Decade

Iris de Weerdt

16 papers receiving 639 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Iris de Weerdt Netherlands 9 466 350 307 209 137 16 644
Yuh Shan Lee Singapore 8 376 0.8× 350 1.0× 244 0.8× 115 0.6× 93 0.7× 17 518
Amy Goodrich United States 7 386 0.8× 397 1.1× 206 0.7× 151 0.7× 82 0.6× 14 561
Magdalena Piotrowska Poland 4 429 0.9× 400 1.1× 222 0.7× 101 0.5× 84 0.6× 7 536
Guenter Fingerle-Rowson Switzerland 11 394 0.8× 455 1.3× 204 0.7× 137 0.7× 65 0.5× 28 550
Vaishalee P. Kenkre United States 13 208 0.4× 258 0.7× 120 0.4× 260 1.2× 78 0.6× 37 456
Dominique Penther France 12 258 0.6× 239 0.7× 108 0.4× 117 0.6× 122 0.9× 32 440
Tamia Nguyen Australia 7 328 0.7× 204 0.6× 109 0.4× 77 0.4× 175 1.3× 15 465
Claes Karlsson Sweden 9 260 0.6× 199 0.6× 169 0.6× 69 0.3× 117 0.9× 19 399
Ewa Wąsik‐Szczepanek Poland 10 279 0.6× 158 0.5× 196 0.6× 75 0.4× 68 0.5× 44 396
B. Ceglarek Poland 9 379 0.8× 305 0.9× 145 0.5× 72 0.3× 95 0.7× 15 425

Countries citing papers authored by Iris de Weerdt

Since Specialization
Citations

This map shows the geographic impact of Iris de Weerdt's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Iris de Weerdt with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Iris de Weerdt more than expected).

Fields of papers citing papers by Iris de Weerdt

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Iris de Weerdt. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Iris de Weerdt. The network helps show where Iris de Weerdt may publish in the future.

Co-authorship network of co-authors of Iris de Weerdt

This figure shows the co-authorship network connecting the top 25 collaborators of Iris de Weerdt. A scholar is included among the top collaborators of Iris de Weerdt based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Iris de Weerdt. Iris de Weerdt is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

16 of 16 papers shown
1.
Lameris, Roeland, Jurjen M. Ruben, Fleur S. van de Bovenkamp, et al.. (2023). A bispecific T cell engager recruits both type 1 NKT and Vγ9Vδ2-T cells for the treatment of CD1d-expressing hematological malignancies. Cell Reports Medicine. 4(3). 100961–100961. 23 indexed citations
2.
Weerdt, Iris de, Roeland Lameris, Jurjen M. Ruben, et al.. (2021). A Bispecific Single-Domain Antibody Boosts Autologous Vγ9Vδ2-T Cell Responses Toward CD1d in Chronic Lymphocytic Leukemia. Clinical Cancer Research. 27(6). 1744–1755. 43 indexed citations
3.
Lameris, Roeland, Jurjen M. Ruben, Iris de Weerdt, et al.. (2021). Abstract 1855: Potent anti-tumor activity against patient CLL, MM and AML by LAVA-051, a bispecific Vγ9Vδ2-T and type 1 NKT cell engager targeting CD1d. Cancer Research. 81(13_Supplement). 1855–1855. 1 indexed citations
4.
Weerdt, Iris de, Roeland Lameris, George L. Scheffer, et al.. (2020). A Bispecific Antibody Antagonizes Prosurvival CD40 Signaling and Promotes Vγ9Vδ2 T cell–Mediated Antitumor Responses in Human B-cell Malignancies. Cancer Immunology Research. 9(1). 50–61. 32 indexed citations
5.
Hofland, Tom, Iris de Weerdt, Aldo Jongejan, et al.. (2020). Functional Differences Between EBV‐ and CMV‐Specific CD8+ T cells Demonstrate Heterogeneity of T cell Dysfunction in CLL. HemaSphere. 4(2). e337–e337. 4 indexed citations
6.
Weerdt, Iris de, Tom Hofland, Renate de Boer, et al.. (2019). Distinct immune composition in lymph node and peripheral blood of CLL patients is reshaped during venetoclax treatment. Blood Advances. 3(17). 2642–2652. 79 indexed citations
7.
Hofland, Tom, Iris de Weerdt, Renate de Boer, et al.. (2019). PB1877 DISSECTION OF THE EFFECTS OF JAK AND BTK INHIBITORS ON THE FUNCTIONALITY OF HEALTHY AND MALIGNANT LYMPHOCYTES. HemaSphere. 3(S1). 855–855. 1 indexed citations
8.
Hofland, Tom, Renate de Boer, Iris de Weerdt, et al.. (2019). Natural Killer Cell Hypo-responsiveness in Chronic Lymphocytic Leukemia can be Circumvented In Vitro by Adequate Activating Signaling. HemaSphere. 3(6). e308–e308. 20 indexed citations
9.
Hofland, Tom, Iris de Weerdt, Renate de Boer, et al.. (2019). Dissection of the Effects of JAK and BTK Inhibitors on the Functionality of Healthy and Malignant Lymphocytes. The Journal of Immunology. 203(8). 2100–2109. 16 indexed citations
10.
Weerdt, Iris de, Tom Hofland, Roeland Lameris, et al.. (2018). Improving CLL Vγ9Vδ2-T–cell fitness for cellular therapy by ex vivo activation and ibrutinib. Blood. 132(21). 2260–2272. 40 indexed citations
11.
Weerdt, Iris de, Tom Hofland, Johan A. Dobber, et al.. (2018). First Evidence of Restoration of T and NK Cell Compartment after Venetoclax Treatment. Blood. 132(Supplement 1). 1860–1860. 5 indexed citations
12.
Weerdt, Iris de, et al.. (2017). Incidence and management of toxicity associated with ibrutinib and idelalisib: a practical approach. Haematologica. 102(10). 1629–1639. 112 indexed citations
13.
Hofland, Tom, Iris de Weerdt, Ester B. M. Remmerswaal, et al.. (2015). EBV-Specific CD8+ T-Cells Are Not Functionally Impaired in Chronic Lymphocytic Leukemia. Blood. 126(23). 1723–1723. 1 indexed citations
14.
Weerdt, Iris de, Tom Hofland, Roeland Lameris, et al.. (2015). Chronic Lymphocytic Leukemia (CLL) Cells Are Susceptible to γδ-T Cell Mediated Killing, Provided CLL-Derived γδ-T Cell Dysfunction Can be Reversed. Blood. 126(23). 2914–2914. 4 indexed citations
15.
Burger, Jan A., Michael J. Keating, William G. Wierda, et al.. (2014). Safety and activity of ibrutinib plus rituximab for patients with high-risk chronic lymphocytic leukaemia: a single-arm, phase 2 study. The Lancet Oncology. 15(10). 1090–1099. 260 indexed citations
16.
Weerdt, Iris de, Eric Eldering, M. H. van Oers, & Arnon P. Kater. (2013). The biological rationale and clinical efficacy of inhibition of signaling kinases in chronic lymphocytic leukemia. Leukemia Research. 37(7). 838–847. 3 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Yuh Shan Lee Breakdown of academic impact, for papers by Amy Goodrich Breakdown of academic impact, for papers by Magdalena Piotrowska Breakdown of academic impact, for papers by Guenter Fingerle-Rowson Breakdown of academic impact, for papers by Vaishalee P. Kenkre Breakdown of academic impact, for papers by Dominique Penther Breakdown of academic impact, for papers by Tamia Nguyen Breakdown of academic impact, for papers by Claes Karlsson Breakdown of academic impact, for papers by Ewa Wąsik‐Szczepanek Breakdown of academic impact, for papers by B. Ceglarek
Rankless by CCL
2026